Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$1.26
Пред. закрытие
$1.46
Вчерашний диапазон
$1.22 - $1.46
Диапазон 52 нед.
$0.44 - $3.04
Объем торговли
1.244M
МС
$231.776M
P/E
--
EPS
$-0.91
Обзор компании
NASDAQ
Century Therapeutics Inc. (Ticker: IPSC) is an innovative biotechnology firm at the forefront of allogenic cell therapy, primarily focused on transforming cancer treatment regimens. Utilizing its advanced induced pluripotent stem cell (iPSC) technology, the company aims to develop groundbreaking off-the-shelf therapeutic solutions that enhance patient outcomes and broaden treatment accessibility. With a robust pipeline of clinical-stage assets and strategic partnerships that strengthen its competitive advantage, Century Therapeutics is well-prepared to make substantial contributions to the cell therapy market, offering attractive opportunities for investors seeking high-impact growth in the biotech sector.
СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира25 NORTH 38TH STREET, PHILADELPHIA, PA, UNITED STATES, 19104
IPSC focuses on developing genetically engineered cell therapies. The company operates in the biotechnology sector, targeting innovative treatments for various medical needs, including regenerative medicine and immune-related diseases.
IPSC operates within the biotechnology industry. It faces competition from companies that develop cell and gene therapies, such as CRISPR Therapeutics, Editas Medicine, and other firms engaged in regenerative medicine and immune-modulation technologies.
IPSC's revenue mainly comes from collaboration agreements, licensing partnerships, and advancements in its proprietary cell engineering platforms. The success of its therapies in clinical trials and regulatory approvals plays a vital role in driving revenue.
Risks include the inherent uncertainty of developing early-stage biotechnology products, lengthy regulatory approval processes, market competition, and challenges in scaling commercial operations. Biotech investments often carry high volatility based on trial results and market sentiment.
No, IPSC does not currently distribute dividends. As a biotechnology company primarily focused on research and development, it reinvests earnings into advancing its therapies and technologies instead of prioritizing dividend payments.
IPSC leverages its proprietary platform to engineer immune cells and regenerative cell products. Its novel approach to developing therapeutic solutions offers specialization that differentiates it from competitors in advanced regenerative medicine and immunotherapy.
IPSC has growth opportunities in expanding clinical trials, gaining regulatory approvals, and establishing partnerships with global pharmaceutical firms. Success in its therapies could lead to addressing unmet medical needs, opening up additional revenue streams.
Investors should consider IPSC’s pipeline progress, competitive position in the biotechnology market, and future potential for regulatory success. Due to its pre-commercial stage, valuation may fluctuate based on clinical updates, collaboration deals, and investor sentiment in the biotech space.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.
